Erbitux sBLA For Head And Neck Cancer Delayed By "Independent Review" Process
This article was originally published in The Pink Sheet Daily
ImClone and Bristol-Myers Squibb originally intended to submit supplemental BLA by second-quarter 2005. ImClone now anticipates filing in the fourth quarter following an additional review of the Phase III study's primary endpoint. Delay means ImClone will miss milestone payment.
You may also be interested in...
Firms originally planned a second quarter submission, but delayed to allow for an independent review of the Phase III trial. The review confirms the study met its primary efficacy endpoint of locoregional control.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.